These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34959409)

  • 1. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units.
    Weinelt FA; Stegemann MS; Theloe A; Pfäfflin F; Achterberg S; Schmitt L; Huisinga W; Michelet R; Hennig S; Kloft C
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.
    Liebchen U; Weinelt F; Scharf C; Schroeder I; Paal M; Zoller M; Kloft C; Jung J; Michelet R
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0183121. PubMed ID: 34871092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept.
    Hartman SJF; Swaving JGE; van Beek SW; van Groen BD; de Hoop M; van der Zanden TM; Ter Heine R; de Wildt SN
    Front Pharmacol; 2020; 11():592204. PubMed ID: 33390970
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
    Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
    J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics: development of a medical intensive care unit-specific gentamicin dosing nomogram.
    Watling SM; Kisor DF
    Ann Pharmacother; 1993 Feb; 27(2):151-4. PubMed ID: 8439687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients.
    Roggeveen LF; Guo T; Driessen RH; Fleuren LM; Thoral P; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers P
    Front Pharmacol; 2020; 11():646. PubMed ID: 32499697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients.
    Colin PJ; Jonckheere S; Struys MMRF
    Clin Pharmacokinet; 2018 Nov; 57(11):1435-1447. PubMed ID: 29512049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.